GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BeiGene Ltd (HKSE:06160) » Definitions » Net Change in Cash

BeiGene (HKSE:06160) Net Change in Cash : HK$-5,765 Mil (TTM As of Mar. 2024)


View and export this data going back to 2018. Start your Free Trial

What is BeiGene Net Change in Cash?

Net Change in Cash is calculated as the total of Cash Flow from Operations , Cash Flow from Investing, Cash Flow from Financing, and Effect of Exchange Rate Changes.

BeiGene's Net Change in Cash for the three months ended in Mar. 2024 was HK$-2,961 Mil. Its Net Change in Cash for the trailing twelve months (TTM) ended in Mar. 2024 was HK$-5,765 Mil.

BeiGene Net Change in Cash Historical Data

The historical data trend for BeiGene's Net Change in Cash can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BeiGene Net Change in Cash Chart

BeiGene Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Net Change in Cash
Get a 7-Day Free Trial Premium Member Only Premium Member Only -936.06 5,963.00 23,341.49 -3,953.82 -5,381.37

BeiGene Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Net Change in Cash Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2,600.05 -957.13 -2,667.03 820.75 -2,961.38

BeiGene Net Change in Cash Calculation

BeiGene's Net Change in Cash for the fiscal year that ended in Dec. 2023 is calculated as

Net Change in Cash= Cash Flow from Operations+Cash Flow from Investing+Cash Flow from Financing+Effect of Exchange Rate Changes
=-9039.476+468.619+3252.61+-63.119
=-5,381

BeiGene's Net Change in Cash for the quarter that ended in Mar. 2024

Net Change in Cash=Cash Flow from Operations+Cash Flow from Investing+Cash Flow from Financing+Effect of Exchange Rate Changes
=-2413.959+-1641.508+1269.618+-175.532
=-2,961

Net Change in Cash for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was HK$-5,765 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BeiGene Net Change in Cash Related Terms

Thank you for viewing the detailed overview of BeiGene's Net Change in Cash provided by GuruFocus.com. Please click on the following links to see related term pages.

BeiGene (HKSE:06160) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BeiGene Ltd (HKSE:06160) » Definitions » Net Change in Cash
Comparable Companies
BNTX ALNY BMRN MRNA RPRX LEGN INCY UTHR SRPT TECH OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 HKSE:02269 XBRU:ARGX SZSE:300122 OCSE:GMAB
Traded in Other Exchanges
BGNE:USA 49BA:Germany 688235:China B1GN34:Brazil
Address
c/o Mourant Governance Services (Cayman) Limited, 94 Solaris Avenue, Camana Bay, Grand Cayman, CYM, KY1-1108
Website
https://www.beigene.com
BeiGene Ltd is a commercial-stage biotechnology company. It is engaged in the discovery and development of molecularly targeted and immuno-oncology drugs for the treatment of cancer. The company has developed a proprietary cancer biology platform that addresses the importance of tumor-immune system interactions and the value of primary biopsies in developing new models to support its drug discovery effort. It has developed clinical-stage drug candidates that inhibit the important oncology targets Bruton's tyrosine kinase, or BTK; RAF dimer protein complex and PARP family of proteins, and an immuno-oncology agent that inhibits the immune checkpoint protein receptor PD-1. Its geographical segments are China, the United States, and the Rest of the world.
Executives
Jpmorgan Chase & Co. 2502 Approved lending agent
Oyler John Victor 2101 Beneficial owner
The Capital Group Companies, Inc. 2201 Interest of corporation controlled by you
Baker Felix James 2201 Interest of corporation controlled by you
Baker Julian Charles 2201 Interest of corporation controlled by you
Baker Bros. Advisors (gp) Llc 2201 Interest of corporation controlled by you
Baker Brothers Life Sciences Capital, L.p. 2201 Interest of corporation controlled by you
Hhlr Advisors, Ltd. 2102 Investment manager
Hhlr Fund, L.p. 2101 Beneficial owner
Amgen Inc. 2101 Beneficial owner
Hillhouse Capital Advisors, Ltd. 2102 Investment manager
Gaoling Fund, L.p. 2101 Beneficial owner
Fidelity Management & Research Company
Fmr Co., Inc.

BeiGene (HKSE:06160) Headlines

No Headlines